Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $108.0M | $115.3M | $127.9M | $136.2M | $172.5M | $176.0M | $203.9M | $236.2M | $262.6M | $266.8M | $260.3M | $299.9M | $350.2M | $413.0M | $491.3M | $552.8M | $694.5M | $932.0M | $898.8M | $1,097.1M |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, IDEXX Laboratories, Inc.'s last 12-month Operating Income is $1,130.1M, based on the financial report for Dec 31, 2024 (Q4 2024).
Over the last year, IDEXX Laboratories, Inc.'s Operating Income growth was 3.0%. The average annual Operating Income growth rates for IDEXX Laboratories, Inc. have been 9.4% over the past three years, 15.4% over the past five years.
Over the last year, IDEXX Laboratories, Inc.'s Operating Income growth was 3.0%, which is higher than industry growth of (0.3%). It indicates that IDEXX Laboratories, Inc.'s Operating Income growth is Good.